CompanyUnited States
Aurobindo Pharma USA Inc, East Windsor, NJ – FDA Inspections
Inspection records and compliance data for Aurobindo Pharma USA Inc in East Windsor, New Jersey. 5 FDA inspections on record (1 OAI), last inspected June 04, 2026.
Company Profile
This profile covers Aurobindo Pharma USA Inc based in East Windsor, New Jersey, United States.
FDA Inspection History
- FDA inspections
- 5
- OAI
- 1
- VAI
- 1
- NAI
- 2
- Unclassified
- 1
- Form 483s
- 0
- Warning letters
- 0
First inspected July 29, 2011. Last inspected June 4, 2026.
Most cited issue areas
- Contamination, chemical or physical change, deterioration1 inspection
- Failure to develop written procedures1 inspection
- Failure to review ADE information1 inspection
What you get
A document
One file.
- One FDA document, such as a Form 483
- Yours for life in your Library
- Each has its own price
The profile
All the documents, plus intelligence about the company.
- Every Aurobindo Pharma USA Inc document on file
- The KRA score, which a single document does not include
- Observations and inspection history
Access
This, for every company on KeyPedia.
- Combine profiles in one search
- Search across any modality: products, industry types, drugs, devices and recalls
- Track everything as it changes
- Other agencies too, such as EMA, Health Canada and UK MHRA
FDA inspections (5)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| June 4, 2026 | Not classified | Human Drugs | 1316082 |
| May 15, 2024 | OAI | Human Drugs · Drug Quality Assurance | 1238442 |
| December 12, 2014 | NAI | Human Drugs · Drug Quality Assurance | 908515 |
| May 30, 2012 | NAI | Human Drugs · Bioresearch Monitoring | 783745 |
| July 29, 2011 | VAI | Human Drugs · Bioresearch Monitoring | 736360 |
Company Information
Name
Aurobindo Pharma USA Inc
Registration numbers
- FEI
- 3008460374
Address
279 Princeton Hightstown Rd, East Windsor, New Jersey 08520, United States
Country
United States
ID: a8dbf5ca-1af1-432a-85b6-5a0c7499eaa5
Comes with the profile
KRA (KeyPedia Risk Analysis)
How likely the FDA is to take enforcement action in the next 12 months.
Example18-month trend